Boric Acid Marco Viti Cutaneous Solution 3% Antiseptic 200ml

NAME
MARCO VITI BORIC ACID 3% SKIN SOLUTION

PHARMACOTHERAPEUTIC CATEGORY
Antiseptics and disinfectants.

ACTIVE PRINCIPLES
Boric acid.

EXCIPIENTS
Sodium benzoate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium hydroxide, propylene glycol, purified water.

INDICATIONS
Antiseptic for the disinfection of minor burns and irritated or chapped skin areas. The solution is also used in the form of local buffers with a decongestant action. Boric acid is indicated as an antibacterial for the treatment of acne.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity to the active substance or to any of the listed excipients; extensive skin lesions; children under 3 years of age.

DOSAGE
External use: apply as needed on the affected area. Adults: Boric acid can be applied directly once or twice a day to inflamed areas in case of chapped, irritated or dry skin, abrasions, mild burns, sunburn, wind burns or insect bites. Children over 3 years of age: Boric acid can be applied directly once or twice a day to inflamed areas associated with chapped, irritated or dry skin, diaper dermatitis, mild sunburn, sunburn, wind sunburn or sunburn. insects.

STORAGE
Keep the container tightly closed to protect from light.

WARNINGS
Excessive and prolonged application on large areas or on broken skin can cause accumulation toxicity. The medicinal product must not be used for ophthalmic use. The cutaneous solution drug contains: sodium benzoate; parahydroxybenzoates; propylene glycol.

INTERACTIONS
There is no known interaction between boric acid for external use and other medicinal products.

SIDE EFFECTS
The absorption of boric acid through intact skin is less than 0.5%; however it may increase if accidentally administered systemically or applied to wounds or lesions. The following are the undesirable effects of boric acid which occurred in case of toxicity from accumulation, after prolonged exposure and following systemic absorption. These effects are organized according to the MedDRA System Organ Class. Insufficient data are available to establish the frequency of the individual effects listed. Skin and subcutaneous tissue disorders: dermatitis, rashes, alopecia. Gastrointestinal disorders. Gastro-intestinal disorders: nausea, vomiting, diarrhea. Metabolism and nutrition disorders: anorexia. Endocrine disorders: menstrual disorders. Blood and lymphatic system disorders: anemia. Musculoskeletal and connective tissue disorders: weakness. Psychiatric Disorders: Confusion. Nervous system disorders: convulsions. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug.

PREGNANCY AND BREASTFEEDING
No clinical data on exposed pregnancies are available. Animal studies are insufficient to detect effects on embryonic / fetal development. The potential risk for humans is not known, however if the drug is used in accordance with the intended use, absorption is low and the risk of systemic effects is minimal. There are no data on the use of the drug during lactation and it is not known whether this active ingredient passes into breast milk. However, since the absorption of the drug may be considered negligible, it is very unlikely that significant quantities reach breast milk.